Breaks Categories: News

WednesdayJan 24, 2018 3:13 pm

CannabisNewsBreaks – True Leaf Medicine International Ltd. (CSE: MJ) (FSE: TLA) (OTCQB: TRLFF) Secures New Equity Financing

True Leaf Medicine International (CSE: MJ) (FSE: TLA) (OTCQB: TRLFF) this morning said it has raised C$14 million in equity financing that will enable the life cannabis company to move forward with its medicinal cannabis facility. True Leaf raised C$10M in a Regulation A+ public equity offering priced at C$0.70 per share, making it the first Canadian-listed company to successfully conduct such an offering. Additionally, the company said it is currently working toward the close of a $4,051,654.60 non-brokered private placement via the sale of 5,788,078 common shares at a price of C$0.70 per share, available to Canadian investors only.…

Continue Reading

WednesdayJan 24, 2018 2:46 pm

CannabisNewsBreaks – Liberty Leaf Holdings Ltd. (CSE: LIB) (OTCQB: LIBFF) (FSE: HN3P) Secures $2M in Private Placement

On January 22, Liberty Leaf Holdings Ltd. (CSE: LIB) (OTCQB: LIBFF) (FSE: HN3P) said that it closed a non-brokered private placement financing of 5,000,000 units at a price of $0.40 each. Each unit consists of one common share and one-half of one transferable share purchase warrant. Each whole warrant entitles the holder to further purchase one common share for a period of up to twenty-four months at a price of $0.60. The company also issued 259,485 finder's units with the same entails. The company received total gross proceeds of $2,000,000 from the offering which it intends to use toward fast-tracking…

Continue Reading

ThursdayJan 18, 2018 11:09 am

CannabisNewsBreaks – ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Subsidiary Receives Import License from Australia

ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF), through wholly-owned subsidiary ABcann Australia Pty Ltd., this morning announced that it has received an import license from the Federal Office of Drug Control in Australia. Following receipt of necessary approvals, including approval from the TSX Venture Exchange, ABcann intends to supply medicinal cannabis to the Australian market via the Australian Department of Health’s Therapeutic Goods Administration (“TGA”) Special Access Scheme. “This import license is a key milestone towards generating revenue through ABcann’s network of physicians, pharmacists and patients, and advancing the use of medical cannabis,” Barry Fishman, chief executive officer of ABcann,…

Continue Reading

TuesdayJan 09, 2018 11:47 am

CannabisNewsBreaks – DOJA Cannabis Company Ltd. (CSE: DOJA) (OTC: DJACF) Completes $12.5 Million Private Placement

Premium cannabis lifestyle brand DOJA Cannabis Company Ltd. (CSE: DOJA) (OTC: DJACF) this morning announced the closing of its previously outlined non-brokered private placement of subscription receipts, whereby Aphria Inc. (TSX: APH) (OTC: APHQF) and Koicha Partners LP acquired from DOJA an aggregate of roughly nine million subscription receipts at a price per unit of $1.39, generating gross proceeds of $12.5 million. Per the update, this financing is intended to support the strategic positioning of Hiku Brands Company Ltd., the anticipated combined company resulting from the merger of DOJA and Tokyo Smoke. “We're thrilled to have strategic partners in Aphria…

Continue Reading

TuesdayJan 09, 2018 10:08 am

CannabisNewsBreaks – Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Responds to Cole Memo Repeal

Emerging-stage pharmaceutical and IP development company Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) this morning issued a follow-up statement to the memorandum issued by Attorney General Jeff Sessions on January 4, 2018, concerning marijuana enforcement and the repeal of the Cole Memo. In the update, Veritas noted that the AG’s decision largely relates to the recreational cannabis marketplace, in which individual states have allowed sales over the last 24 months. Conversely, the company notes, it does not affect the medical cannabis marketplace. As such, Veritas intends to build on its commitment to advancing the science of medical cannabis…

Continue Reading

MondayJan 08, 2018 12:34 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) CEO Recaps 2017 Highlights

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), a biosciences company that has developed delivery technologies to improve absorption of bioactive compounds, this morning announced the release of a 2017 year-end summary penned by CEO Chris Bunka. The release highlights what Bunka refers to as Lexaria’s “busiest and most productive” year to date, including details about the company’s progress toward strengthening its balance sheet, ongoing research and development efforts related to its patented DehydraTECH™ absorption and palatability enhancing technology, its preparations for increased demand in both Californian and Canadian markets and its ongoing efforts to strengthen its intellectual property portfolio. Bunka…

Continue Reading

MondayJan 08, 2018 12:28 pm

CannabisNewsBreaks – NeutriSci International Inc. (TSX-V: NU) (OTCQB: NRXCF) (FRANKFURT: 1N9) Enters Research and Development MOU with Scientus Pharma Inc.

NeutriSci International (TSX-V: NU) (OTCQB: NRXCF) (FRANKFURT: 1N9) this morning announced that it has entered into a major research and development (R&D) Memorandum of Understanding (“MOU”) with Scientus Pharma Inc. In accordance of the terms set forth in the MOU, the two companies have agreed to share their technologies to develop, test, produce, and distribute a medical cannabinoid product for current retail distribution networks throughout Canada. "This Scientus Pharma partnership helps position us at the forefront of developing new and innovative cannabinoid based medical products in Canada. Scientus Pharma, along with its existing partnerships, is sure to be a dominant…

Continue Reading

FridayJan 05, 2018 10:19 am

CannabisNewsBreaks – ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Names New Chief Marketing Officer

ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) this morning announced its appointment of Sung Kang as its new chief marketing officer, effective January 8, 2018. Kang brings more than 17 years of marketing experience to the ABcann team, having previously served as the head of marketing for the Mike’s Beverage Company, Canada’s leading ready-to-drink and cider business. “Sung is a great addition to the leadership team,” Barry Fishman, CEO of ABcann, stated in the news release. “We believe his marketing expertise combined with his experience in the alcohol and consumer health industries will prove invaluable to ABcann’s future growth. He…

Continue Reading

ThursdayJan 04, 2018 11:35 am

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Begins Trading on OTCQX Best Market

OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, this morning announced that Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a biosciences company that has developed delivery technologies to improve absorption of bioactive compounds, has qualified to trade on the OTCQX® Best Market. Subsequently, Lexaria has upgraded from the OTCQB® Venture Market, beginning today. “Lexaria has made notable progress over the past twelve months in all aspects of its business, and will receive even more recognition by upgrading to OTCQX,” Chris Bunka, chief executive officer of Lexaria, stated in the news release. “Lexaria…

Continue Reading

TuesdayJan 02, 2018 10:32 am

CannabisNewsBreaks – ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Receives Cannabis Oil Production License from Health Canada

ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) this morning announced that it has been licensed by Health Canada to produce medical cannabis oils. Per the update, Health Canada will conduct a final inspection when ABcann has saleable extracted finished products. ABcann expects to complete this process in the first quarter of 2018. “Receipt of the license to produce cannabis oils is a major milestone in our pursuit to provide our medical cannabis patients with additional product formats that can be precisely dosed,” Barry Fishman, CEO of ABcann, stated in the news release. “The expansion and innovation of our product lines…

Continue Reading